Potentiation of the bystander effect by immunization combined with suicide gene therapy

Advances in Experimental Medicine and Biology

Volumn 451, Issue , 1998, Pages 125-131

  Ramesh, Rajagopal ^a   Marrogi, Aizen J ^a   Munshi, Anupama ^a   Freeman, Scott M ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GANCICLOVIR; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; RETROVIRUS; SPLEEN LYMPHOCYTE; SUICIDE GENE; TUMOR CELL LINE;

EID: 0031723741     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5357-1_20     Document Type: Article

References (25)

1. S.M. Freeman, C.S. McCune, C.N Abboud, G.N. Abraham, 1992: Treatment of ovarian cancer using HSV-TK gene-modified cells. Hum Gene Ther. 3, 342-349.
2. S.M Freeman, K.A Whartenby,. D.S Koeplin,. F.L Moolten,. C.N. Abboud, G.N. Abraham, 1992: Tumor regression when a fraction of the tumor mass contains the HSV-TK gene. J Cell Bioch. 16F: (abstract no. 47).
3. S.M Freeman,., C.N. Abboud, K.A. Whartenby, C.H. Packman, D.S. Koeplin, F.L Moolten,. G.N.Abraham, 1993: The Bystander Effect: Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53: 5274-5283.
4. S.M Freeman, R. Ramesh, M. Shastri, A. Munshi, A. Jensen, A.J. Marrogi, 1995: The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Letters 92, 167-174.
5. R. Kolberg, 1994: The bystander effect in gene therapy: great but how does it work. J NIH Res. 62-64.
6. L. Seachrist, 1994: Successful gene therapy has researchers looking for the bystander effect. J Natl. Cancer Inst. 86, 82.
7. W.L. Bi, L.M. Parysek, R. Warnick, P.J. Stambrook, 1993: In vitro evidence that metabolic cooperation is responsible for the Bystander Effect observed with HSV-tk retroviral gene therapy. Hum. Gene Ther. 4, 725-731.
8. A.A Elshami, A. Saavedra, H. Zhang, J.C. Kucharczuk, D.C. Spray, G.I. Fishman, K.M. Amin, L.R. Kaiser, S.M. Albelda, 1996: Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3, 85-92.
9. K.W. Culver, Z. Ram, E.H Oldfield, R.M. Blaese, 1992: Regression of brain tumors using gene-modified cells. Science. 256, 1550-1552.
10. S.M.Freeman, R. Ramesh, A.J. Marrogi, A Jensen, C.N Abboud,. 1994: In vivo studies on the mechanism of the bystander effect. Cancer Gene Ther. 1, 326.
11. B.M. Colombo, S. Benedetti, S. Ottolenghi, M. Mora, B. Pollo, G. Poli, G. Finocchiaro, 1995: The "bystander effect": Association of U87 cell death with ganciclovir mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. 6, 763-772.
12. Vile, R.G., Nelson, J.A., Castleden, S., Chong, H., and Hart, I.R. 1994: Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-TK gene involves an immune component. Cancer Res. 54, 6228-6234.
13. Whartenby, K.A., Abboud, C.N., Marrogi, A.J., Ramesh, R., and Freeman, S.M. 1995: The biology of cancer gene therapy. Lab Invest. 72, 131-145.
14. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann,J.L.KlatzmannD. 1993: Regression of established macroscopic liver metastasis after in situ transduction of a suicide gene. Proc Natl Acad Sci. USA 90, 7024-7028.
15. R. Ramesh, A.J. Marrogi, A. Munshi, C.N. Abboud, S.M. Freeman, 1996: In-vivo analysis of the "Bystander effect": A cytokine cascade. Exp. Hematol. 24, 829-838.
16. R.G.Vile, S.C. Castleden, J. Marshall, R. Comle-John, C. Upton, H.Chong, 1997: Generation of a Th-1 like immune response in an non-immunogenic tumor: HSV-tk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int. J. Cancer. 71, 267-274.
17. D. Barba, J. Hardin, M. Sadelain, F.H. Gage,. 1994: Development of anti-tumor immunity following thymidine kinase mediated killing of experimental brain tumors. Proc Natl Acad Sci. USA 91, 4348-4352.
18. R. Ramesh, A. Munshi, C.N. Abboud, A.J. Marrogi, S.M. Freeman, 1996: Expression of co-stimulatory molecules: B7 and ICAM up-regulation following treatment with the suicide gene. Cancer Gene Then 3, 373-384.
19. Freeman, S.M., Ramesh, R., Marrogi, A.J. 1997: Immune system in suicide gene therapy. Lancet 3, 2-3.
20. E.M. Southern, 1975: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol. Biol. 98, 53.
21. C.D. Fermin, M.A. Gerber, J. Torre-Bueno, 1992: Color thresholding and objective quantification in bio-imaging. J Microscopy 167, 85-96.
22. I. Gery, R.K. Gershon, B.H. Waksman, 1972: Potentiation of the T lymphocyte response to mitogens 1. The responding cell. J Exp. Med. 136, 128-142.
23. K. Nakano, Okugawa, K., Furuichi, H., Matsui, Y., Sohmura, Y, 1989: Augmentation of the generation of cytotoxic T lymphocytes against syngeneic tumor cells by recombinant tumor necrosis factor. Cell Immunol 120, 154-164.
24. E.A. Carswell, et al., 1975: An endotoxin induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670.
25. T.J. Schall, K.B. Bacon, 1994: Chemokines, leukocyte trafficking and inflammation. Curr Opin Immunol 6, 865-873.